Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Accounts Receivable	0.46	0.78	0.24
Other Receivables	0.67	-	0.01
Receivables	1.13	0.78	0.26
Inventory	3.06	9.63	0.81
Prepaid Expenses	5.09	1.97	4.53
Other Current Assets	1.84	1.09	0.67
Total Current Assets	207.45	13.47	6.26
Property, Plant & Equipment	8.4	9.37	7.22
Other Long-Term Assets	6.71	3.16	3.16
Total Assets	222.56	26	16.65
Accounts Payable	13.65	12.87	9.45
Accrued Expenses	28.61	17.94	9.46
Current Portion of Leases	1.84	2.06	1.86
Total Current Liabilities	44.1	32.86	20.77
Long-Term Leases	-	1.11	3.17
Total Liabilities	44.1	33.97	23.95
Common Stock	0	-7.97	-7.3
Shareholders' Equity	178.47	-7.97	-7.3
Total Liabilities & Equity	222.56	26	16.65
Total Debt	1.84	3.17	5.03
Net Cash (Debt)	194.5	-3.17	-5.03
Working Capital	163.35	-19.4	-14.51
Tangible Book Value	178.47	-7.97	-7.3
Machinery	10.3	9.02	7.55
Construction In Progress	0.15	3.59	-
Leasehold Improvements	0.8	0.44	0.44

Source: S&P Capital IQ. Standard template. Financial Sources.